Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Resmed (RSMDF) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to $311.2 million.

  • Resmed's Free Cash Flow rose 806.55% to $311.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year increase of 2873.06%. This contributed to the annual value of $1.7 billion for FY2025, which is 2764.81% up from last year.
  • Per Resmed's latest filing, its Free Cash Flow stood at $311.2 million for Q4 2025, which was up 806.55% from $414.4 million recorded in Q3 2025.
  • Over the past 5 years, Resmed's Free Cash Flow peaked at $557.9 million during Q1 2025, and registered a low of -$93.0 million during Q3 2021.
  • Its 5-year average for Free Cash Flow is $242.4 million, with a median of $251.6 million in 2023.
  • In the last 5 years, Resmed's Free Cash Flow crashed by 17126.32% in 2021 and then surged by 154198.39% in 2023.
  • Quarter analysis of 5 years shows Resmed's Free Cash Flow stood at $189.5 million in 2021, then crashed by 46.54% to $101.3 million in 2022, then surged by 146.31% to $249.5 million in 2023, then increased by 15.43% to $288.0 million in 2024, then increased by 8.07% to $311.2 million in 2025.
  • Its Free Cash Flow stands at $311.2 million for Q4 2025, versus $414.4 million for Q3 2025 and $508.2 million for Q2 2025.